Advertisement

Fever and Cervical Lymphadenopathy

  • Berenise Gamez-Gonzalez
  • Marco Antonio Yamazaki-Nakashimada
Chapter

Abstract

  • Kawasaki disease (KD) should be considered in the differential diagnosis of any prolonged or unexplained fever in childhood

  • Cervical lymphadenopathy is an uncommon clinical feature in KD, but can be the only initial clinical finding

  • When a patient with KD develops new fever within 36 h after the last dose of intravenous immunoglobulin (IVIG) infusion, IVIG resistance has to be considered

  • Macrophage activation syndrome is a potential complication of KD

  • Treatment of refractory KD includes repeated IVIG infusions with infliximab and/or corticosteroids

Keywords

Kawasaki disease Intravenous immunoglobulin Cervical lymphadenopathy 

References

  1. 1.
    Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708–33.CrossRefGoogle Scholar
  2. 2.
    McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99.CrossRefGoogle Scholar
  3. 3.
    Gamez-Gonzalez LB, Hamada H, Llamas-Guillen BA, Ruiz-Fernandez M, Yamazaki-Nakashimada M. BCG and Kawasaki disease in Mexico and Japan. Hum Vaccin Immunother. 2017;13(5):1091–3.CrossRefGoogle Scholar
  4. 4.
    Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153(1):117–21.CrossRefGoogle Scholar
  5. 5.
    Shrestha S, Wiener HW, Olson AK, Edberg JC, Bowles NE, Patel H, Portman MA. Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol. 2011;128(3):677–80.CrossRefGoogle Scholar
  6. 6.
    Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr (Oslo, Norway : 1992). 2001;90(1):40–4.CrossRefGoogle Scholar
  7. 7.
    Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7.CrossRefGoogle Scholar
  8. 8.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40.CrossRefGoogle Scholar
  9. 9.
    Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12.CrossRefGoogle Scholar
  10. 10.
    Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, Atz AM, Printz BF, Baker A, Vetter VL, Newburger JW. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831–835.e833.CrossRefGoogle Scholar
  11. 11.
    Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17(12):1144–8.CrossRefGoogle Scholar
  12. 12.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.CrossRefGoogle Scholar
  13. 13.
    Tremoulet A, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, Tamamoto A, Erdem G, Dodd D, Burns J. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161(3):506–12.CrossRefGoogle Scholar
  14. 14.
    Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine. 2012;60(3):681–5.CrossRefGoogle Scholar
  15. 15.
    Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2012;15(1):5.CrossRefGoogle Scholar
  16. 16.
    Wang W, Gong F, Zhu W, Fu S, Zhang Q. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum. 2015;44(4):405–10.CrossRefGoogle Scholar
  17. 17.
    Bode S, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt U, Ehl S. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthitis Res Ther. 2012;14(3):213.CrossRefGoogle Scholar
  18. 18.
    García-Pavón S, Yamazaki-Nakashimada M, Báez M, Borjas-Aguilar K, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol. 2017;36(9):445–51.CrossRefGoogle Scholar
  19. 19.
    Burns J, Glode M. Kawasaki syndrome. Lancet (London, England). 2004;364(9433):533–44.CrossRefGoogle Scholar
  20. 20.
    Rowley A. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J. 2002;21(6):563–5.CrossRefGoogle Scholar
  21. 21.
    Tremoulet A, Jain S, Chandrasekar D, Sun X, Sato Y, Burns J. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30(12):1022–6.CrossRefGoogle Scholar
  22. 22.
    Nofech-Mozes Y, Garty B. Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms. Pediatr Hematol Oncol. 2003;20(8):597–601.CrossRefGoogle Scholar
  23. 23.
    Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, Spiegelblatt L, Bonny Y, Vartian M, Montigny M. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009;30(6):810–7.CrossRefGoogle Scholar
  24. 24.
    Lin K, Chang S, Yu C, Lin S, Liu S, Chao H, Lee M, Wu J, Lee C. Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis. BMJ Open. 2015;5(4):e006703.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Berenise Gamez-Gonzalez
    • 1
  • Marco Antonio Yamazaki-Nakashimada
    • 2
  1. 1.Hospital Infantil de Especialidades de ChihuahuaChihuahuaMexico
  2. 2.Clinical Immunology DepartmentInstituto Nacional de PediatríaMexico CityMexico

Personalised recommendations